Through a dual evaluation approach, this network-based analysis could effectively yield top modules evaluated by the presence of MS FDA-approved drug target genes: HDAC1, IL2RA, KEAP1 and RELA. Other central genes present within top modules are suggested as potential drug targets for MS: GRB2, JAK2, MAPK1 and STAT3. The independent gene set enrichment results of both GeneMSA and IMSGC top modules supported the hypothesis of epigenetic factors involved in dysregulation of genes in MS. The gene discussed is IL2RA; the disease is myeloid sarcoma.